抗癫痫药物撤药时机对胶质瘤患者癫痫复发的影响:一项回顾性观察研究
该回顾性观察研究纳入109例完成抗肿瘤治疗且无癫痫发作的胶质瘤患者,比较短期、中期与长期无癫痫发作后撤除抗癫痫药物(ASM)的癫痫复发风险。结果显示三组复发风险相似,短期组与中期组病因特异性调整风险比(aHR)为0.65(95%CI 0.29-1.46),与长期组为1.04(95%CI 0.52-2.09)。
要点
- 短期无癫痫发作组撤药后复发率为47%(16/34),中期组为31%(10/32),长期组为44%(19/43)。
- 短期组与中期组相比,病因特异性aHR=0.65(95%CI 0.29-1.46),复发风险相似。
- 短期组与长期组相比,病因特异性aHR=1.04(95%CI 0.52-2.09),复发风险相似。
核心结论
- 完成抗肿瘤治疗后,短期、中期与长期无癫痫发作的胶质瘤患者撤除ASM后癫痫复发风险相对相似。
研究设计与样本
- 回顾性观察研究,纳入109例完成抗肿瘤治疗且无癫痫发作的胶质瘤患者,按无癫痫发作时长分为短期组(≥3个月且<12个月)、中期组(12-24个月)和长期组(≥24个月)。
主要发现
- 短期组31%(34/109)、中期组29%(32/109)、长期组39%(43/109)的患者分别纳入分析。
- 短期组癫痫复发率为47%(16/34),中期组为31%(10/32),长期组为44%(19/43)。
- 短期组与中期组相比,病因特异性aHR=0.65(95%CI 0.29-1.46);短期组与长期组相比,病因特异性aHR=1.04(95%CI 0.52-2.09)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Withdrawal of antiseizure medication treatment (ASM) can be considered after completion of antitumour treatment in glioma patients who no longer suffer from seizures. We compared the risk for recurrent seizures after ASM withdrawal between patients with short-term, medium-term versus long-term seizure freedom after antitumour treatment. METHODS: In this retrospective observational study, the primary outcome was time to recurrent seizure, from the starting date of no ASM treatment up to 36 months follow-up. Cox proportional hazards models were used to study the effect of risk factors on time to recurrent seizure. Stratification was done with information known at baseline. Short-term seizure freedom was defined as ≥ 3 months, but < 12 months; medium-term as 12-24 months; and long-term as ≥ 24 months seizure freedom from the date of last antitumour treatment. RESULTS: This study comprised of 109 patients; 31% (34/109) were in the short-term, 29% (32/109) in the medium-term, and 39% (43/109) in the long-term group. A recurrent seizure was experienced by 47% (16/34) of the patients in the short-term, 31% (10/32) in the medium-term, and 44% (19/43) in the long-term group. Seizure recurrence risk was similar between patients in the short-term group as compared to the medium-term (cause-specific adjusted hazard ratio [aHR] = 0.65 [95%CI = 0.29-1.46]) and long-term group (cause-specific aHR = 1.04 [95%CI = 0.52-2.09]). CONCLUSIONS: Seizure recurrence risk is relatively similar between patients with short-term, medium-term, and long-term seizure freedom after completion of antitumour treatment.
引用
- van der Meer PB, Dirven L, Fiocco M, et al. Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study. J Neurooncol. 2023. PMID: 37755633. doi:10.1007/s11060-023-04450-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。